

Dennie Meijer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6366680/publications.pdf>

Version: 2024-02-01

17
papers

133
citations

1477746

6
h-index

1281420

11
g-index

19
all docs

19
docs citations

19
times ranked

96
citing authors

#	ARTICLE	IF	CITATIONS
1	Predicting early outcomes in patients with intermediate- and high-risk prostate cancer using prostate-specific membrane antigen positron emission tomography and magnetic resonance imaging. <i>BJU International</i> , 2022, 129, 54-62.	1.3	10
2	Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer. <i>European Urology Oncology</i> , 2022, 5, 146-152.	2.6	9
3	Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer. <i>Cancers</i> , 2022, 14, 1169.	1.7	15
4	Standardised uptake values as determined on prostate-specific membrane antigen positron emission tomography/computed tomography is associated with oncological outcomes in patients with prostate cancer. <i>BJU International</i> , 2022, 129, 768-776.	1.3	7
5	Biochemical Persistence of Prostate-specific Antigen after Robot-assisted Laparoscopic Radical Prostatectomy: Tumor localizations using PSMA PET/CT imaging. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.120.252528.	2.8	11
6	Nuclear Imaging for Bone Metastases in Prostate Cancer: The Emergence of Modern Techniques Using Novel Radiotracers. <i>Diagnostics</i> , 2021, 11, 117.	1.3	6
7	SUVs Are Adequate Measures of Lesional ¹⁸ F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1264-1269.	2.8	2
8	Management impact of 18F-DCFPyL PET/CT in hormone-sensitive prostate cancer patients with biochemical recurrence after definitive treatment: a multicenter retrospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2960-2969.	3.3	8
9	Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography in the Evaluation of Initial Response in Candidates Who Underwent Salvage Radiation Therapy after Radical Prostatectomy for Prostate Cancer. <i>Journal of Urology</i> , 2021, 205, 1100-1109.	0.2	4
10	Reply by Authors. <i>Journal of Urology</i> , 2021, 205, 1108-1109.	0.2	0
11	Reply by Authors. <i>Journal of Urology</i> , 2021, 205, 1662-1662.	0.2	0
12	The Predictive Value of Preoperative Negative Prostate Specific Membrane Antigen Positron Emission Tomography Imaging for Lymph Node Metastatic Prostate Cancer. <i>Journal of Urology</i> , 2021, 205, 1655-1662.	0.2	10
13	External Validation of Two Nomograms Developed for 68Ga-PSMA-11 Applied to the Prostate-specific Membrane Antigen Tracer 18F-DCFPyL: Is Prediction of the Optimal Timing of Salvage Therapy Feasible?. <i>European Urology Open Science</i> , 2021, 28, 47-51.	0.2	2
14	External Validation and Addition of Prostate-specific Membrane Antigen Positron Emission Tomography to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: an International Multicenter Study. <i>European Urology</i> , 2021, 80, 234-242.	0.9	35
15	18F-DCFPyL Uptake in an Incidentally Detected Follicular Lymphoma by PET/CT Performed for Biochemically Recurrent Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2020, 45, e96-e97.	0.7	2
16	Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer. <i>PLoS ONE</i> , 2020, 15, e0239414.	1.1	6
17	Prostate Cancer Development Is Not Affected by Statin Use in Patients with Elevated PSA Levels. <i>Cancers</i> , 2019, 11, 953.	1.7	6